A debate about what to do about outpatient treatment of malaria has been underway for some time. Unfortunately, a debate (in the political sense) is what it sometimes resembles. There has for a while been private, and recently increasingly public, evidence that some of those involved have the tendency to perceive 'sides' in what is a complex and technical discussion in which there may be many right answers. This should not obscure the fact that there is a large measure of agreement. There is a near unanimous agreement that multi-drug resistant falciparum malaria is a major and growing problem in Africa and elsewhere. There is wide agreement that in the short to medium term some combination of antimalarial drugs rather than monotherapy will be needed. Where and when a change needs to be made, whether every combination will need to contain an artemisinin drug and how drug combinations can be afforded are important and difficult technical issues which are legitimate topics for debate. In some places the answers are fairly clear-cut; in many they are not. In several geographical areas a decision to change to combination therapy needs to made very soon, and in a few it clearly needs to be made now.
The main argument of this editorial is that we need to acknowledge that there is no perfect or universal solution to the question 'what is the best antimalarial drug policy for 2004?'. Decisions about what to deploy as first-line treatment, and when, need to depend on a combination of factors that are always going to be unique to a particular country or region. A calm acceptance of that fact, and an honest and balanced assessment of the pros and cons of various options are far more likely to win round reasonable doubters, and to attract the substantial donor funding which is undoubtedly needed, than a strongly argued but ultimately (if unconsciously) partisan approach or a belief that there is only one answer which should be pushed at all costs.
A unified global approach to a combination drug policy has served us well for the treatment of tuberculosis and leprosy -it is not going to be the right approach for malaria for many reasons. This may seem so obvious as not to need stating, but recently the debate over combination therapy for malaria has become increasingly polarized and occasionally heated; the fact that there are many partly right answers and no perfect ones is sometimes lost. Take artemisinin combination therapy. Some funding bodies (especially those from the USA) treat one class of drugs, now widely used by hundreds of thousands for two decades, as experimental and only to be Tropical Doctor July 2004, 34 used within very strictly controlled safety studies. On the other hand some others (from Europe) will only fund studies which use an artemisinin in them. Eminent scientists have publicly branded the Global Fund, the major funding body for action (as opposed to research) negligent for their antimalarial drug policy. They have questioned the competence of the malaria experts on that body'. Meanwhile various activist groups make forceful statements outlining what should be done -views which often owe more to the intensity of their passion for good than to the scientific basis of their argumentsoccasionally in private getting dangerously close to accusing those who have a different view of consciously causing the deaths of thousands of children.
The current situation is very complex with many facets. However, they can be reduced to three broad issues:
• drug resistance patterns • the local epidemiology of malaria • the cost of drugs relative to local income.
Areas with limited drug resistance have many more effective antimalarial drug combinations to choose from than those where malaria is resistant to many drugs. Equally, there is clearly a considerable practical difference between a high-transmission area in Africa where the average individual gets infected three or more times a year with falciparum malaria and an area of Asia where the predominant species is vivax and most individuals go years without being infected. Cost is probably the most difficult but most important part of the equation. Put at its simplest, if an antimalarial drug which is twice as good as the current treatment can only be afforded by a third of the population, it is unlikely deploying it as first-line treatment will lead to a startling improvement in public health. A drug which is affordable in, say, South-East Asia may well be a major financial barrier in rural Africa, and in some situations a slightly less good drug which can be afforded by all may be a better solution than an excellent drug affordable only by the richer members of society (who are less likely to get malaria anyway).
Let us briefly review a few of the facts which are known, and some of the areas of relative uncertainty.
I. Everywhere people look for chloroquine resistance they will find it. Resistance rates have shot up recently in West Africa and the remaining parts of Asia where it is still used. Despite this, several countries in Africa and Asia currently have chloroquine as first-line treatment as official policy (e.g. Yemen and Ghana) or even more commonly as the drug that is actually used for treatment irrespective of official drug policy. Both doctors and patients are understandably reluctant to change from chloroquine as they have always known it to be the best treatment -where it works it is quick, cheap, safe and effective. Unfortunately, it no longer works so reliably everywhere. Because chloroquine brings down the temperature and makes people feel better, irrespective of the underlying cause, and because most of those for whom the treatment fails will get better initially (resistance is usually partial rather than complete), clinicians often underestimate the extent of chloroquine resistance in their area until it reaches exceptionally high levels. All governments who currently use chloroquine as first-line treatment should be planning to changemany (e.g. Ghana) already are. 2. Drug resistance rates for sulfadoxine/pyrimethamine (SIP) are already high in much (but not all) of Asia, East Africa and increasingly elsewhere. Parasitological failure rates of over 40% by day 14 of treatment are common in some parts of East Africa where SIP remains first-line treatment/. It is not true to say that SP is no longer a useful drug -in many parts of the world it remains highly effective and cheap. On the other hand, with a few exceptions (Malawi for example), it has not survived for long after it has been deployed as first-line treatment. 3. Deploying a combination of drugs has the advantage that even if there are parasites resistant to one drug the other drug is likely to kill the malaria. Many of the combinations of drugs are more effective than you would predict from their individual activity when used alone. 4. Artemisinin drugs are highly effective drugs which, as monotherapy, are liable to high failure rates. However, when used with another effective antimalarial drug they produce some of the highest cure rates for any drug combination. For case management of individual cases where cost is no barrier artemisinin combination drugs are almost certainly the best solution in areas with a substantial burden of multi-drug resistance, as they combine high efficacy, short courses and are well tolerated.'. Because of their efficacy and ease of use there has been a strong push to promote artemisinincontaining drug combinations (ACT) as a universal answer to multi-drug resistant malaria. I will say at once that I am strongly in favour of ACTs, and find some of the reasons given for not deploying them overstated. There are, however, some good reasons not to rush into saying that artemisinin combinations for everybody, now, are always the answer, and these should be outlined in a transparent way: this is the only way to engage with those who have legitimate doubts. 5. Drug combinations are inevitably more expensive than the two drugs used alone. Artemisinin drugs are more expensive than many other drugs (SIP, amodiaquine, chlorproguanil-dapsone [Lapdap]). At present, currently available artemisinin fixed combinations cost around US$I-2.50 for a treatment course -current monotherapy costs between US$0.15-30. This is not a major problem in most of Asia, both because incomes are higher and because malaria is relatively rare: it is a serious concern in much of Africa. It is probable that ACT costs will come down in price, and it is possible they will come down a long way but some places need to make a change now. Gambling on the possibility that something we want to happen will definitely do so has significant risks. In some countries these risks are clearly worthwhile because the situation is desperate -but not necessarily in all. If even just some of the increase in cost were to passed on to those who are suffering from malaria it would almost certainly mean that some people would not be able to afford treatment. Probably, and more importantly, it is likely to lead to many others who 130 can afford the drugs, but only with great difficulty, delaying treatment -and in malaria delay kills", 6. It is often stated that artemisinins can delay or even reverse drug resistance in the second drug in the combination. That it can delay resistance developing to a new antimalarial where there is no resistance already may true, but it is actually quite rare. Whether reversing widespread drug resistance has already occurred is much less certain. It could perhaps happen in some situations; in fact there is fairly strong evidence from Thailand that it has indeed happened with mefloquine. The probability of reversing resistance in areas of very high transmission, or where monotherapy continues to exist in the market alongside ACT is, however, much smaller. All of these apply to much of Africa. There, where an artemisinin is used with a failing drug (e.g. with chloroquine, SIP or amodiaquine in areas where there is high resistance to that drug), the combination has not been particularly successful--". Once there are appreciable levels of drug resistance to a drug, adding an artemisinin to it will seldom be the answer. This is a significant problem, animal models have been hyped up to a ridiculous level in some quarters. Many thousands of courses have been prescribed in both adults and children and they are clearly reasonably safe, and certainly much safer than using an ineffective drug for a lifethreatening disease. The effect of repeated dosing in young children has not yet been studied sufficiently to be completely certain that there is no risk. Neither is there any current human data to suggest this will be a major problem, especially compared to using ineffective drugs. 9. The exception to a blanket endorsement of their safety is in pregnancy. When women who are known to be pregnant have taken artemisinins in controlled studies followed to birth (the best part of 1000 women, mainly in Asia) there has been nothing to suggest a problem'', There is, however, animal evidence that for a short time in early pregnancy in animals artemisinins may be teratogenic. Whilst there is nothing to suggest this is true in humans, these data cannot simply be ignored until the situation is a bit clearer. In later pregnancy the current advice is that artemisinins should only be used if there are no good alternatives -which in some parts of the world (especially Southeast Asia) is the case'', Where artemisinins are clearly the best antimalarial option to treat a pregnant woman they should definitely be used -the dangers of undertreating malaria in pregnancy far outweigh the theoretical risks. Trials which are underway or planned should help to provide more data on women who are in the second two trimesters of pregnancy in Africa. The question that it may take some time to settle is whether the fetuses of women who take artemisinins in the first few days/weeks of pregnancy have problems -at which point most women will be unaware they are pregnant. The data will have to be accumulated from women who are given artemisinins and subsequently find they are pregnant, and this will inevitably take some time.
The importance of this is that if arternisinins are deployed as first-line treatment in areas of high malaria transmission large numbers of women in early pregnancy will inevitably take them, unaware they are pregnant, and where this is not strictly necessary it is probably not ideal. 10. Those who advocate an expensive solution over a less expensive one, largely or solely because it has attractive but unproven long-term public health advantages in reducing drug resistance, must keep in mind the fact that unless they come bearing subsidies it will be the poor individuals who will pay some or all of the cost now for a theoretical public good in years to come.
The bad news, therefore, is that cheap and effective monotherapy is a thing of the past in much of the world, yet in many places this has not yet been realized, let alone acted on. The good news is that many excellent drug combinations exist; most, but not all, contain artemisinin drugs. The main down side to this is cost -until the cost issue is tackled and (more importantly) a sustainable answer found those who do not need to change will be rightly wary of doing so. Balancing efficacy, cost and other benefits and disadvantages must therefore be sensitive to the local situations. Arguing for an expensive combination option in Country X because it is needed now in an area haifa continent away, or may be needed in Country X sometime in the future, will often be the wrong thing to do.
The current situation is serious. Three things in particular stand in the way of progress:
• failure by some clinicians and public health officials to realize the gravity of the situation on the ground until it is too late • a counter-productive belief by a vocal few that a onesize-fits-all policy should be pushed at all costs • above all lack of money.
Both the first and the last of these are made worse when those who put forward a good case for one possible solution then ruin it by implying that all alternative Tropical Doctor July 2004, 34 solutions put forward by others for the local situation are 'wrong'. Some may be, but in most counties there are several reasonable solutions, each with up and down sides. Intelligent people who are innately sceptical of the need for change (and most people will avoid change unless there is a good reason for it) are made more sceptical both by experts appearing to undermine one another and by people patently over-selling their own solution. Meanwhile all of the good long-term solutions to antimalarial drug resistance in the poorer areas are going to need substantial amounts of money, almost certainly from external sources, if they are to have any impact on those who need the drugs most. So far only a fraction of what is needed has been pledged. It is doubtful that stronglyworded public accusations levelled at key funding agencies are the most effective way to secure donor support for these agencies. Lowering the temperature of the debate, increasing the database of local knowledge about drugs, accepting that there are many possible solutions to what is a very complex problem, and realizing that they will need to be tailored to local conditions -this is the best way to support clinicians and public health experts who need to make changes to antimalarial drug policy either now or very soon.
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